Literature DB >> 25201199

Splice variants of MDM2 in oncogenesis.

Melissa Rosso1, Danielle E Okoro, Jill Bargonetti.   

Abstract

Many types of human cancers overexpress MDM2 protein. A common characteristic among these cancers is an associated increase in mdm2 splice variants. Provided here is a comprehensive list, based on a literature review, of over 70 mdm2 variants. These variants are grouped according to in-frame versus out-of-frame status and their potential (or ability) to be translated into isoform proteins. We describe the putative functions for these mdm2 splice variant mRNAs, as well as the mechanistic drivers associated with increased mdm2 transcription and splicing. The paradoxical signal transduction functions of the most commonly studied variants mdm2-a,-b and -c are addressed for their outcomes in the presence and absence of wild-type p53. These outcomes vary from tumor promotion to growth arrest. Finally, we present issues in the detection of endogenous MDM2 protein and how many of the antibodies commonly used to detect MDM2 do not present a full picture of the cellular representation of the isoform proteins. This review provides a focusing lens for individuals interested in learning about the complexities of mdm2 mRNAs and their protein isoforms as well as the roles MDM2 isoforms may play in cancer progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201199     DOI: 10.1007/978-94-017-9211-0_14

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  9 in total

1.  MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.

Authors:  Lenora W M Loo; Chong Gao; Yurii B Shvetsov; Danielle R Okoro; Brenda Y Hernandez; Jill Bargonetti
Journal:  Breast Cancer Res Treat       Date:  2018-11-23       Impact factor: 4.872

Review 2.  Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

Review 3.  Alternative splicing and cell survival: from tissue homeostasis to disease.

Authors:  Maria Paola Paronetto; Ilaria Passacantilli; Claudio Sette
Journal:  Cell Death Differ       Date:  2016-09-30       Impact factor: 15.828

4.  MDM2-C Functions as an E3 Ubiquitin Ligase.

Authors:  Jun Yeob Kim; Rusia Lee; Gu Xiao; Dominique Forbes; Jill Bargonetti
Journal:  Cancer Manag Res       Date:  2020-08-24       Impact factor: 3.989

Review 5.  Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

Authors:  Wen Li; Xinhao Peng; Jinyi Lang; Chuan Xu
Journal:  Front Pharmacol       Date:  2020-05-07       Impact factor: 5.810

6.  Alternative Splicing of RAD6B and Not RAD6A is Selectively Increased in Melanoma: Identification and Functional Characterization.

Authors:  Ambikai Gajan; Carly E Martin; Seongho Kim; Milap Joshi; Sharon K Michelhaugh; Ido Sloma; Sandeep Mittal; Steven Firestine; Malathy P V Shekhar
Journal:  Cells       Date:  2019-11-01       Impact factor: 6.600

7.  Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.

Authors:  Melissa Rosso; Alla Polotskaia; Jill Bargonetti
Journal:  Oncotarget       Date:  2015-10-27

Review 8.  The Role of MDM2 in Promoting Genome Stability versus Instability.

Authors:  M Reza Saadatzadeh; Adily N Elmi; Pankita H Pandya; Khadijeh Bijangi-Vishehsaraei; Jixin Ding; Christopher W Stamatkin; Aaron A Cohen-Gadol; Karen E Pollok
Journal:  Int J Mol Sci       Date:  2017-10-23       Impact factor: 5.923

9.  Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.

Authors:  Sana AlQarni; Yazeed Al-Sheikh; Donald Campbell; Mark Drotar; Adele Hannigan; Shelagh Boyle; Pawel Herzyk; Andrew Kossenkov; Kate Armfield; Lauren Jamieson; Mariarca Bailo; Paul M Lieberman; Penelope Tsimbouri; Joanna B Wilson
Journal:  Oncogene       Date:  2018-04-25       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.